Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study

BACKGROUND: Phosphodiesterase‐4 (PDE4) is a promising target in atopic dermatitis (AD) treatment. The pharmacokinetics (PK), safety, and efficacy of crisaborole topical ointment, 2% (formerly AN2728) (Anacor Pharmaceuticals, Palo Alto, CA), a boron‐based benzoxaborole PDE4 inhibitor, were evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Zane, Lee T., Kircik, Leon, Call, Robert, Tschen, Eduardo, Draelos, Zoe Diana, Chanda, Sanjay, Van Syoc, Merrie, Hebert, Adelaide A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084761/
https://www.ncbi.nlm.nih.gov/pubmed/27193740
http://dx.doi.org/10.1111/pde.12872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084761/
https://www.ncbi.nlm.nih.gov/pubmed/27193740
http://dx.doi.org/10.1111/pde.12872

Ejemplares similares